Eric Benevich - 16 Aug 2021 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: NBIX
Reported as of: 16 Aug 2021
Net transaction value: -$504,395
SEC form: 4
Accepted by SEC: 18 Aug 2021, 18:18:10 UTC
Prior SEC filing: 11 May 2023
Next SEC filing: 02 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Attorney-in-Fact

Key filing fact

Eric Benevich filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 18 Aug 2021.

Key facts

This page summarizes Eric Benevich's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Aug 2021, 18:18.

Change

Previous filing in this sequence was filed on 11 May 2023.
Current net transaction value: -$504,395.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBIX transaction

Common Stock

Sale

Transaction value: $504,395
Shares: -5,628
Change %: -27%
Price: $89.62
Shares after: 15,608
Date: 16 Aug 2021
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Footnote F2

Includes 137 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 26, 2021.